Tag: Eliquis
ASA: No Drop in Recurrent Stroke Seen With Apixaban After Cryptogenic Stroke
No significant difference noted in recurrent stroke, symptomatic intracranial hemorrhage for patients receiving apixaban, aspirin
AHA: Apixaban Beneficial for Patients With Subclinical A-Fib
Risk for stroke or systemic embolism lower with apixaban versus aspirin for patients with subclinical a-fib
Rates of Adverse Events Lower With Apixaban for A-Fib in Older Adults
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
Apixaban Seems Safer Than Rivaroxaban for A-Fib
Lower rates seen for ischemic stroke or systemic embolism, GI bleeding or intracranial hemorrhage
Many Patients Take OTC Meds That May Interact With Apixaban
Less knowledge about OTC products with potentially serious interactions linked to increased use
Apixaban Tx Cost in A-Fib Meets U.S. Norms for Reasonable Value
Incremental cost of achieving longer life expectancy within accepted U.S. norm ($53,925/QALY)
Usual Apixaban Dosing OK With One Dose-Reduction Criterion
5 mg apixaban twice daily deemed safe, appropriate for those with one criterion in ARISTOTLE trial
